Assignee
VALNEVA AUSTRIA GMBH
AT·33 granted patents·15 pending applications·128 citations·filing 2013–2025
Top patents by PatentIndex Score
48 records- 0196US11572392B2Mutant fragments of OspA and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2020·Granted Feb 7, 2023·6 cites·23 claims
- 0296US11524064B2Zika virus purificationVALNEVA AUSTRIA GMBH·Filed 2020·Granted Dec 13, 2022·7 cites·18 claims
- 0396US11219681B2Zika virus vaccineVALNEVA AUSTRIA GMBH·Filed 2020·Granted Jan 11, 2022·9 cites·26 claims
- 0495US10744194B2Zika virus purificationVALNEVA AUSTRIA GMBH·Filed 2016·Granted Aug 18, 2020·11 cites·20 claims
- 0595US10639365B2Zika virus vaccineVALNEVA AUSTRIA GMBH·Filed 2016·Granted May 5, 2020·6 cites·20 claims
- 0694US10766931B2Mutant fragments of OspA and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2018·Granted Sep 8, 2020·9 cites·19 claims
- 0794US10357557B2Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereofVALNEVA AUSTRIA GMBH·Filed 2017·Granted Jul 23, 2019·13 cites·15 claims
- 0893US11684669B2CpG-adjuvanted SARS-CoV-2 virus vaccineVALNEVA AUSTRIA GMBH·Filed 2021·Granted Jun 27, 2023·6 cites·30 claims
- 0993US11208439B2Mutant fragments of OspA and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2018·Granted Dec 28, 2021·6 cites·19 claims
- 1093US9975927B2Mutant fragments of OspA and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2015·Granted May 22, 2018·13 cites·11 claims
- 1193US9926343B2Mutant fragments of OspA and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2016·Granted Mar 27, 2018·10 cites·18 claims
- 1292US12195501B2Mutant fragments of OspA and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2021·Granted Jan 14, 2025·1 cites·23 claims
- 1392US2026070950A1Mutant fragments of ospa and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2025·Application pending·0 cites
- 1491US11466058B2Mutant fragments of OspA and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2019·Granted Oct 11, 2022·4 cites·10 claims
- 1591US11331382B2Zika virus purificationVALNEVA AUSTRIA GMBH·Filed 2016·Granted May 17, 2022·4 cites·9 claims
- 1691US10544194B2Mutant fragments of OspA and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2016·Granted Jan 28, 2020·8 cites·9 claims
- 1791US2025018023A1Zika Virus VaccineVALNEVA AUSTRIA GMBH·Filed 2024·Application pending·0 cites
- 1890US10821166B2Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereofVALNEVA AUSTRIA GMBH·Filed 2019·Granted Nov 3, 2020·3 cites·18 claims
- 1989US10668146B2Methods for preparing aluminum precipitate compounds for use in therapeutics and vaccinesVALNEVA AUSTRIA GMBH·Filed 2017·Granted Jun 2, 2020·3 cites·12 claims
- 2088US12102673B2Zika virus vaccineVALNEVA AUSTRIA GMBH·Filed 2023·Granted Oct 1, 2024·0 cites·32 claims
- 2187US11951163B2Zika virus vaccineVALNEVA AUSTRIA GMBH·Filed 2023·Granted Apr 9, 2024·0 cites·58 claims
- 2287US11478540B2Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereofVALNEVA AUSTRIA GMBH·Filed 2021·Granted Oct 25, 2022·1 cites·12 claims
- 2384US12018054B2Multivalent OspA polypeptides and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2018·Granted Jun 25, 2024·3 cites·20 claims
- 2484US2025360191A1Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereofVALNEVA AUSTRIA GMBH·Filed 2025·Application pending·0 cites
- 2583US12324831B2Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereofVALNEVA AUSTRIA GMBH·Filed 2022·Granted Jun 10, 2025·0 cites·19 claims
- 2683US11110170B2Aluminum compounds for use in therapeutics and vaccinesVALNEVA AUSTRIA GMBH·Filed 2020·Granted Sep 7, 2021·1 cites·20 claims
- 2782US2023295245A1Mutant fragments of ospa and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2022·Application pending·0 cites
- 2881US12005111B2Zika virus vaccineVALNEVA AUSTRIA GMBH·Filed 2021·Granted Jun 11, 2024·0 cites·58 claims
- 2981US2023322869A1Mutant fragments of ospa and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2023·Application pending·0 cites
- 3080US9913898B2Aluminum compounds for use in therapeutics and vaccinesVALNEVA AUSTRIA GMBH·Filed 2016·Granted Mar 13, 2018·2 cites·18 claims
- 3180US9884115B2Aluminum compounds for use in therapeutics and vaccinesVALNEVA AUSTRIA GMBH·Filed 2015·Granted Feb 6, 2018·2 cites·14 claims
- 3278US12331084B2Multivalent OspA polypeptides and methods and uses relating theretoVALNEVA AUSTRIA GMBH·Filed 2024·Granted Jun 17, 2025·0 cites·20 claims
- 3377US12527863B2Methods for preparing aluminum precipitate compounds for use in therapeutics and vaccinesVALNEVA AUSTRIA GMBH·Filed 2021·Granted Jan 20, 2026·0 cites·18 claims
- 3473US11357844B2Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereofVALNEVA AUSTRIA GMBH·Filed 2020·Granted Jun 14, 2022·0 cites·20 claims
- 3565US9492537B2Methods and compositions involving immunostimulatory oligodeoxynucleotidesVALNEVA AUSTRIA GMBH·Filed 2014·Granted Nov 15, 2016·0 cites·4 claims
- 3665US2025213667A1Clostridium difficile vaccineVALNEVA AUSTRIA GMBH·Filed 2023·Application pending·0 cites
- 3763US2024026412A1Improved methods of producing a lipidated proteinVALNEVA AUSTRIA GMBH·Filed 2021·Application pending·0 cites
- 3863US2023398210A1Improvements in vaccine formulations for medical useVALNEVA AUSTRIA GMBH·Filed 2021·Application pending·0 cites
- 3962US2015232517A1MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETOVALNEVA AUSTRIA GMBH·Filed 2013·Application pending·0 cites
- 4062US2022298493A1Inactivation process for virusesVALNEVA AUSTRIA GMBH·Filed 2022·Application pending·0 cites
- 4160US8952135B2S. agalactiae antigens I and IIVALNEVA AUSTRIA GMBH·Filed 2013·Granted Feb 10, 2015·0 cites·11 claims
- 4260US2014212448A1Klebsiella antigensVALNEVA AUSTRIA GMBH·Filed 2013·Application pending·0 cites
- 4357US2015250865A1MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETOVALNEVA AUSTRIA GMBH·Filed 2015·Application pending·0 cites
- 4455US2015010595A1Vaccines comprising an immunostimulatory peptide and an immunostimulatory oligodeoxynucleic acid moleculeVALNEVA AUSTRIA GMBH·Filed 2014·Application pending·0 cites
- 4554US2024293531A1Inactivated sars-cov-2 virus vaccineVALNEVA AUSTRIA GMBH·Filed 2021·Application pending·0 cites
- 4651US9248180B2IC31 nanoparticlesVALNEVA AUSTRIA GMBH·Filed 2014·Granted Feb 2, 2016·0 cites·17 claims
- 4749US2016362480A1Novel oprf/i fusion proteins, their preparation and useVALNEVA AUSTRIA GMBH·Filed 2016·Application pending·0 cites
- 4846US12514912B2Compositions comprising three OspA fusion proteins for medical useVALNEVA AUSTRIA GMBH·Filed 2021·Granted Jan 6, 2026·0 cites·24 claims
Join the waitlist — get patent alerts
Get an alert when VALNEVA AUSTRIA GMBH files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →